All In Biotech

Drug Trial Radar · NCT07386002

The GLIOMAX Study: MT027 Allogeneic CAR-T for Recurrent Glioma

A Phase II, Open-Label, Multicenter Study With a Safety Run-In to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of MT027 Administrated Intracerebroventricularly in Patients With Recurrent or Progressive Glioblastoma (WHO Grade 4)

Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Nov 30, 2026

Primary completion

Dec 13, 2028

Study completion Jul 31, 2029

Sponsor

Lead sponsor
T-MAXIMUM Pharmaceutical IncIndustry
Sponsor type
Industry
Collaborators
Virginia Contract Research Organization Co., Ltd.
First posted
Feb 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase II trial to evaluate the safety, tolerability, efficacy, and PK/ pharmacodynamic profiles of MT027 injected via ICV in participants with recurrent or progressive IDH-wildtype glioblastoma (WHO 2021 CNS Grade 4), who have previously received standard of care (SOC) therapy. Each participant will undergo screening, treatment (receiving MT027 at a dose of 3×10\^7 cells), safety follow-up, and long-term follow-up periods. MT027 will be given via ICV injection on Day 1 \& Day 15 of the first 28-day cycle. If the participant does not experience any unacceptable toxicities and disease progress in the first cycle, additional treatment may be continued bi-weekly in a 28-day cycle (Days 1 \& Day 15 of the 28-day cycle) until intolerable toxicity, disease progression, withdrawal from the study, or death, whichever comes first. After the last dose, there will be a safety follow-up period lasting for 1 year and then a long-term follow-up up to 15 years.

Conditions

  • Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype

Interventions

  • Intracerebroventricular injection of MT027 UCAR-T Cell targeting B7H3Biological

    MT027 will be injected intracerebroventricularly at a dose of 3×10\^7 cells on Day 1 \& Day 15 of each 28-day treatment cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence rate of Dose-limiting toxicity (DLT)Time frame: From the first dose to 2 weeks after the second dose
  2. 12-month overall survival (OS) rateTime frame: From the first dose to 12 months after the treatment

Locations

4 sites in 2 countries. Site status is shown where the registry gives one.

  • The Johns Hopkins Sidney Kimmel Cancer Center

    Baltimore, Maryland

  • Hualien Tzu Chi Hospital

    Hualien City, Taiwan

  • Chang Gung Memorial Hospital, Kaohsiung

    Kaohsiung City, Taiwan

  • Chang Gung Memorial Hospital, Linkou

    Taoyuan, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.